Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | In-line → Outperform | Evercore ISI | |
| 11/4/2024 | Outperform → Mkt Perform | Raymond James | |
| 8/8/2024 | $13.00 → $15.00 | Neutral → Buy | BofA Securities |
| 5/9/2024 | $7.00 | Underweight → Equal-Weight | Morgan Stanley |
| 10/24/2023 | $11.00 | Neutral → Buy | Citigroup |
| 10/18/2023 | $8.00 | Underweight → Neutral | JP Morgan |
| 10/17/2023 | Overweight → Neutral | Cantor Fitzgerald | |
| 9/29/2023 | $9.00 → $17.00 | Hold → Buy | Stifel |
4 - Editas Medicine, Inc. (0001650664) (Issuer)
SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)
SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)
SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on its in vivo progress and pipeline development in 1Q 2025 Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI
Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine's proprietary targeted LNP as a key step forward toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Initiated process to partner or out-license reni-cel to focus resources on in vivo pipeline development Company to present data and discuss strategic update in a Company-sponsored Webinar today at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced its achievement of in vivo preclinical proof of concept of hematopoietic
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates. "We made significant progress in all three pillars of our strategy this quarter, particularly reni-cel as we shared a substantial clinical update mid-year and continued to enroll and dose at an accelerated pace. With these data, we are hig
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine's commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company's current and future pipeline of products. "As we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren's caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen
CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company's Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas' drug discovery team and activities related to Editas Medicine's pipeline of experimental medicines across all therapeutic areas and indications. "Earlier this year, we shared our vision to be a leader in programable in vivo gene editing, and I couldn't be happier that Linda is joining Editas to help make this vision a reality. Linda has an outstanding track record of inventing or contributing to the fo
Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 1 0 2 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Editas Medicine, presenting an average target of $10.0, a high estimate of $15.00, and a low estimate of $7.00. This current average rep
Oppenheimer analyst Jay Olson maintains Editas Medicine (NASDAQ:EDIT) with a Perform and maintains $12 price target.
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant
10-Q - Editas Medicine, Inc. (0001650664) (Filer)
8-K - Editas Medicine, Inc. (0001650664) (Filer)
8-K - Editas Medicine, Inc. (0001650664) (Filer)
4 - Editas Medicine, Inc. (0001650664) (Issuer)
4 - Editas Medicine, Inc. (0001650664) (Issuer)
4 - Editas Medicine, Inc. (0001650664) (Issuer)
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December: Guggenheim's Inaugural Healthcare Innovation ConferenceFormat: Fireside ChatDate: Tuesday, November 12Time: 4:00 p.m. ETLocation: Boston, MA Stifel 2024 Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, November 19Time: 1:50 p.m. ETLocation: New York, NY 7th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside ChatDate: Tuesday, December 3Time: 1:20 p.m. ETLocation: Coral Gables, FL To access the live webcasts of Editas Medicine
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on its in vivo progress and pipeline development in 1Q 2025 Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI
Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine's proprietary targeted LNP as a key step forward toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Initiated process to partner or out-license reni-cel to focus resources on in vivo pipeline development Company to present data and discuss strategic update in a Company-sponsored Webinar today at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced its achievement of in vivo preclinical proof of concept of hematopoietic
Evercore ISI upgraded Editas Medicine from In-line to Outperform
Raymond James downgraded Editas Medicine from Outperform to Mkt Perform
BofA Securities upgraded Editas Medicine from Neutral to Buy and set a new price target of $15.00 from $13.00 previously